Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP1391 | DOI: 10.1530/endoabs.49.EP1391

ECE2017 Eposter Presentations: Thyroid Thyroid (non-cancer) (260 abstracts)

The impact of age and gender on the presentation and prognosis of medullary thyroid cancer – an Israeli multicenter study

Orit Twito 1 , Simona Grozinsky-Glasberg 2 , Carlos Benbassat 4, , Sigal Llevy 3 , Gideon Bachar 5, , David J Gross 2 & Dania Hirsch 6,

1Institute of Endocrinology, Meir Medical Center, Kfar-Sava, Israel; 2Neuroendocrine Tumor Unit, Endocrinology and Metabolism Service, Hadassah-Hebrew Universirt Medical Center, Jerusalem, Israel; 3Academic College of Tel-Aviv Yaffo, Tel-Aviv, Israel; 4Institute of Endocrinology, Assaf Harofe Medical Center, Zerifin, Israel; 5Otorhinolaryngology, Rabin Medical Center, Beilinson Hospital, Pethch-Tikva, Israel; 6Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; 7Institute of Endocrinology, Rabin Medical Center, Beilinson Hospital, Petach-Tikva, Israel.

Background: Data regarding the effect of gender and age on medullary thyroid cancer (MTC) presentation and prognosis is limited. Although older age and male sex were found to correlate with poorer prognosis in some studies, this correlation may reflect differences in MTC presentation between sex and age groups, or a mixture of hereditary and sporadic MTC forms.

Objective: To evaluate the impact of age and sex on the presentation and outcomes of MTC.

Methods: Epidemiological and clinical data of MTC patients was extracted from a joint registry of four medical centers in Israel.

Results: The study included 193 MTC patients (106 females, age 48.9±18.6, median 51), who were followed for 10.1±9.4 years. Female gender was associated with smaller tumor diameter (22.3 vs 28.7 mm, P=0.032), lower rate of lymph nodes involvement (42/70, 60% vs 49/64, 76.6%, P=0.044) and lower rate of distant metastases (11/87, 12.6% vs 23/75, 30.7%, P=0.007). Although females achieved higher cure rates (47/97, 48.5% vs 20/72, 27.8%, P=0.007), disease related mortality and all cause mortality did not differ between the genders. Patients aged <45 year at diagnosis had higher rates of hereditary familial forms of MTC (32/74, 43.2% vs 3/114, 2.6% .4%, P<0.0001). Analysis of the sporadic MTC cases (n=137) revealed that younger age at presentation was associated with higher number of metastatic lymph nodes (19.7±23.5 vs 10.2±9.3, P=0.05) and more therapeutic interventions during the follow-up (62.9% vs 33.7%, P=0.04). However, cure rate and disease related mortality were similar between the age groups.

Conclusions: In concert with previous literature, female MTC patients present with milder disease and achieve higher cure rates than males. However, younger age in the sporadic MTC form is associated with more advanced disease at presentation. Neither age nor gender affected disease related mortality.

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.